Short answer: it starts working from the first injection, but three different clocks are running and they are usually mixed into one
The drug reaches peak concentration a median of 24 hours after an injection, with a range of 8 to 72 hours, and reaches steady state after 4 weeks of weekly dosing. The effect you can feel runs on a different clock: the label says tirzepatide "delays gastric emptying" and that "the delay is largest after the first dose and this effect diminishes over time". The weight figures everyone quotes run on a third clock entirely, because they are 72 week results from a trial whose dose escalation alone took 20 weeks. Nothing is wrong when month one does not look like the headline number. The three clocks are set out separately below, each with the source it comes from.
Clock 1: the drug in your blood
These figures come from section 12.3 of the prescribing information, and they are the only ones in this article measured in hours.
- Time to peak concentration: a median of 24 hours, range 8 to 72 hours.
- Elimination half-life: approximately 5 to 6 days, which is what makes once weekly dosing possible.
- Steady state: "Steady-state plasma tirzepatide concentrations were achieved following 4 weeks of once weekly administration."
The practical consequence of a 5 to 6 day half-life with weekly dosing is that your first injection at any strength produces the lowest exposure you will have at that strength. Concentrations build over roughly four doses before levelling off. This is also why an injection taken a day late is not a reset, and why section 2.3 allows a missed dose to be taken "as soon as possible within 4 days (96 hours)" before skipping it.
Clock 2: the effect you can feel
Section 12.2 is three short lines, and two of them matter here: "Tirzepatide decreases calorie intake. The effects are likely mediated by affecting appetite", and "Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time."
That second sentence is the one almost nobody quotes, and it explains an experience thousands of people describe as a problem: the first week or two feels dramatic, then the fullness softens. On the label's account, part of that is the expected course of the gastric emptying effect rather than a sign of failure. The appetite effect and the weight effect are not described as fading in the same way, which is why the two should not be read as one thing.
What has not actually been measured
There is no published day by day appetite curve for tirzepatide. The most cited appetite study, Heise and colleagues in Diabetes Care, assessed appetite and energy intake at baseline and at week 28, not during the first days. So pages that tell you appetite drops "within 24 to 72 hours" are extrapolating from the time to peak concentration, not reporting a measurement. The honest version is that the drug is at its peak level about a day after the injection and that many people report an early change, with no trial data on exactly when.
Clock 3: the scale
SURMOUNT-1 randomised 2,539 adults to 5 mg, 10 mg, 15 mg or placebo for 72 weeks. Mean weight change at week 72 was 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, against 3.1% on placebo. Those are the numbers that circulate, and they come with a design detail that is almost always dropped: the trial included a 20 week dose-escalation period. Nobody in the 15 mg group was taking 15 mg before week 20.
So the 20.9% figure describes a 72 week course of treatment, most of it at a dose that took five months to reach. It is not a month one expectation, and comparing your week 6 against it compares two different clocks.
The three clocks on one timeline
| Point in treatment | What is documented | What it is not |
|---|---|---|
| First 24 hours | Median time to peak concentration, range 8 to 72 hours. Gastric emptying delay is at its largest after this first dose. | Not a measured appetite onset. No trial reports appetite day by day. |
| Weeks 1 to 4 | Concentrations building toward steady state. The whole period is spent at 2.5 mg, which the label says is for initiation and is not an approved maintenance dosage. | Not a fair test of the treatment's effect, because the maintenance dosages start at 5 mg. |
| Week 4 onward | Steady state reached. The earliest the label allows a move to 5 mg, and increases thereafter come after at least 4 weeks on the current dose. | Not a plateau. The dose at this point is still an on-ramp. |
| Around week 20 | The point at which SURMOUNT-1 participants had completed escalation to their assigned dose. | Not a milestone in your own treatment. Your schedule is your prescriber's. |
| Week 72 | The timepoint behind the 15.0%, 19.5% and 20.9% figures. | Not an endpoint for treatment. SURMOUNT-4 showed weight returning when treatment stopped. |
Things that do not change the speed
- Where you inject. The label states that "similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm". Site rotation matters for your skin, not for absorption speed. Our guide to the best GLP-1 injection site for weight loss goes through why.
- Time of day, and meals. Section 2.4: administer "once weekly at any time of day, with or without meals".
- Which day of the week. The day can be changed "as long as the time between the two doses is at least 3 days (72 hours)".
What to measure instead of waiting
Four weeks is the unit this drug works in, so one week's weight tells you almost nothing and a trend over four tells you something. Three things are worth having in front of you before the next appointment: weeks at the current dose, the weight trend across those weeks, and any side effects with the day they occurred relative to the injection. Keeping them in a GLP-1 tracker rather than in your head is what turns "I think it is slowing down" into a line somebody can read. If it feels like nothing is happening at all, that is a conversation with your prescriber rather than a reason to change anything yourself; why the dose gets increased covers what they are weighing.
Frequently asked questions
Does Zepbound work from the first injection?
Pharmacologically yes. Concentrations peak a median of 24 hours after the first dose, and the gastric emptying delay is described as largest after that first dose. Whether you notice it is another matter, and no trial has measured it day by day.
Why did my appetite come back a few days after the shot?
Two documented things can contribute. Concentrations fall between weekly doses, with an elimination half-life of about 5 to 6 days, and the gastric emptying effect is described as diminishing over time. Neither means the treatment has stopped working.
How long until I lose weight?
No labelled figure exists for a first week or first month. The published numbers are 72 week results, from a trial that spent its first 20 weeks escalating doses. Judging progress over four week blocks matches the way the dosing schedule itself is built.
How long does it take for Zepbound to suppress appetite?
The honest answer is that it has not been measured in a published trial at a daily resolution. What is documented is a median 24 hour time to peak concentration, a gastric emptying delay largest after the first dose, and an appetite reduction measured at week 28 against placebo.
Is 2.5 mg supposed to do anything?
It is the initiation dose and the label states it "is not approved as a maintenance dosage". Its job is to reduce the risk of gastrointestinal adverse reactions on the way up, not to deliver the treatment effect.
I am four weeks in and nothing has happened. What now?
Four weeks is the entire initiation period, so you have not yet had a maintenance dosage. Tell your prescriber what the four weeks looked like and let them decide the next step. Nothing on this page is a reason to change a dose by yourself.
Related reading
- Why increase the Zepbound dose?, with the gain and the cost of each step
- Zepbound maintenance dose after goal weight, and what SURMOUNT-4 found when treatment stopped
- Do Zepbound side effects start right away?, the same timing question from the side effect direction
- Zepbound reviews, patient ratings against the trial numbers
- GLP-1 tracker app, for a weight and dose trend you can actually read
Sources
- ZEPBOUND (tirzepatide) US prescribing information, Eli Lilly and Company. Section 12.3 for time to peak concentration, half-life and steady state, section 12.2 for gastric emptying and calorie intake, section 2.1 for the initiation dose, section 2.3 for the missed dose window and section 2.4 for timing and injection sites.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID 35658024. Source of the 72 week weight figures, the trial size and the 20 week dose-escalation period.
- Heise T et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. 2023;46(5):998-1004. PMID 36857477. Appetite and energy intake assessed at baseline and week 28, which is why no day by day onset figure exists.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48. PMID 38078870, for what happened after treatment stopped.
This page summarises published prescribing information and peer-reviewed trial results for general education. Individual responses vary, trial averages are not predictions, and nothing here is medical advice or a dosing instruction. Questions about your own progress belong with your prescriber.
Jabby is free on the App Store and keeps weight, doses and side effects on one timeline, so four weeks of progress is a line rather than a feeling.